Related Experiment Video
Updated: Jun 26, 2026
Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
Spatiotemporal heterogeneity in non-small cell lung cancer: A paradigm shift from characterization to dynamic
1Department of Oncology, The Second People's Hospital of Guiyang, Guiyang, Guizhou 550081, P.R. China.
Abstract:
Treatment of non-small cell lung cancer (NSCLC) has entered the era of precision medicine, characterized by targeted therapies and immunotherapies. However, tumor heterogeneity across spatial and temporal dimensions remains a central cause of therapeutic failure and acquired resistance. Spatial heterogeneity manifests as clonal diversity within a single tumor and between metastatic lesions, while temporal heterogeneity reflects the dynamic evolution of clonal populations under therapeutic pressure. It has proved difficult for traditional static diagnostic and therapeutic models to comprehensively capture this complexity. Advances in technologies such as single-cell sequencing, spatial transcriptomics and liquid biopsy now allow the spatiotemporal evolutionary patterns of NSCLC to be deciphered with unprecedented resolution. Based on these developments, the present review proposed that clinical management strategies need to shift from a static classification paradigm towards a new paradigm of dynamic monitoring and intervention. Emerging strategies are systematically discussed, including evolutionary trap therapy, niche intervention and adaptive therapy, which aim to achieve long-term control of disease progression by steering tumor evolutionary paths, remodeling the tumor microenvironment or leveraging competitive suppression mechanisms. Despite ongoing challenges at the technical, biological and clinical translation levels, a dynamic management framework integrating multi-omics data and intelligent algorithms represents promise for transforming NSCLC into a chronic, controllable disease.
Insights
Precision medicine for non-small cell lung cancer (NSCLC) faces challenges from tumor heterogeneity. A dynamic monitoring and intervention approach, using advanced technologies, offers a new paradigm for managing NSCLC.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Non-small cell lung cancer (NSCLC) treatment is evolving with precision medicine, including targeted therapies and immunotherapies.
- Tumor heterogeneity, both spatial and temporal, is a major obstacle to effective treatment, leading to therapeutic failure and acquired resistance.
- Traditional static models struggle to address the complexity of NSCLC's dynamic nature.
Purpose of the Study:
- To propose a shift from static classification to a dynamic monitoring and intervention paradigm for NSCLC management.
- To review emerging therapeutic strategies that address tumor evolution and heterogeneity.
- To highlight the potential of a dynamic management framework for long-term NSCLC control.
Main Methods:
- Review of recent technological advancements enabling high-resolution analysis of NSCLC spatiotemporal evolution, including single-cell sequencing, spatial transcriptomics, and liquid biopsy.
- Systematic discussion of novel therapeutic strategies such as evolutionary trap therapy, niche intervention, and adaptive therapy.
- Integration of multi-omics data and intelligent algorithms for dynamic disease management.
Main Results:
- Advanced technologies allow for unprecedented resolution in deciphering NSCLC spatiotemporal evolutionary patterns.
- Emerging strategies aim to control disease progression by manipulating tumor evolution, microenvironment, or competitive dynamics.
- A dynamic management framework shows promise for transforming NSCLC into a manageable chronic disease.
Conclusions:
- Clinical management of NSCLC requires a paradigm shift towards dynamic monitoring and intervention to overcome therapeutic resistance.
- Novel strategies focusing on steering tumor evolution and remodeling the tumor microenvironment are crucial for long-term disease control.
- Despite challenges, integrating multi-omics data and AI offers a promising future for managing NSCLC as a chronic condition.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...